BMY Bristol Myers Squibb

Q1 2025 10-Q

Filed: Apr 24, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Bristol Myers Squibb (BMY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 24, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• No new or materially updated risk factors disclosed in the section, risk profile consistent with 10-K
• Regulatory risk from reliance on FDA and EC approvals for key products like Opdivo + Yervoy expansions in HCC and CRC in 2025

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$11.2B

▼ -5.6% YoY

Net Income

$2.5B

▲ +120.6% YoY

Net Margin

21.9%

▲ +12231bp YoY

Source: XBRL data from Bristol Myers Squibb Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Bristol Myers Squibb Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Bristol Myers Squibb

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.